A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

about

Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration.

P2860

Q41077113-CBBE0906-1575-4DC8-9AB0-9A61BB501CA1 Q47801037-540F3733-0C6F-44C1-B9B0-A85B8B6A252D

P2860

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

Item

http://www.wikidata.org/entity/Q41071461

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

@en

type

Item

label

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

@en

prefLabel

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

@en

P1476

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

@en

P2093

Fang-Jung Yu

http://www.w3.org/2001/XMLSchema#string

Hui-Min Hsieh

http://www.w3.org/2001/XMLSchema#string

I-Chen Wu

http://www.w3.org/2001/XMLSchema#string

Meng-Chieh Wu

http://www.w3.org/2001/XMLSchema#string

Ming-Tsang Wu

http://www.w3.org/2001/XMLSchema#string

Tzung-Shiun Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

ACP Journal Club. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding.

A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.

The role of aspirin in cancer prevention.

Aspirin in patients undergoing noncardiac surgery.

P304

130-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ECI.12575

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26640116

http://www.w3.org/2001/XMLSchema#string

P921

aspirin

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

about

P2860

P2860

A long-term risk-benefit analysis of low-dose aspirin in primary prevention.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921